Forte Biosciences, Inc. (FBRX)

Forte Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	45.86	22.24	37.13	41.1	42.04	58.77
Short-Term Investments	-	36.12	-	-	-	-
Cash & Short-Term Investments	45.86	58.37	37.13	41.1	42.04	58.77
Cash Growth	50.62%	57.21%	-9.67%	-2.25%	-28.45%	746.88%
Prepaid Expenses	0.85	2.65	1.04	0.34	0.39	0.96
Other Current Assets	0.45	0.34	0.17	0.07	0.09	0.18
Total Current Assets	47.16	61.35	38.33	41.51	42.52	59.9
Property, Plant & Equipment	0.13	0.08	0.11	-	-	0.1
Long-Term Deferred Charges	-	-	-	-	0.11	0.29
Other Long-Term Assets	0.18	0.14	0.54	0.49	0.68	0.96
Total Assets	47.46	61.56	38.98	42	43.31	61.24
Accounts Payable	5.02	4.88	1.42	1.15	0.95	1.24
Accrued Expenses	4.01	4.2	2.24	2.03	0.81	1.02
Total Current Liabilities	9.03	9.08	3.67	3.18	1.76	2.26
Total Liabilities	9.03	9.08	3.67	3.18	1.76	2.26
Common Stock	0.01	0.01	0	0.02	0.02	0.01
Additional Paid-In Capital	208.08	206.46	153.83	125.84	114.7	110.42
Retained Earnings	-169.65	-154	-118.52	-87.04	-73.17	-51.46
Comprehensive Income & Other	-	0.01	0	-	-	-
Total Common Equity	38.43	52.48	35.31	38.82	41.55	58.98
Shareholders' Equity	38.43	52.48	35.31	38.82	41.55	58.98
Total Liabilities & Equity	47.46	61.56	38.98	42	43.31	61.24
Net Cash (Debt)	45.86	58.37	37.13	41.1	42.04	58.77
Net Cash Growth	50.62%	57.21%	-9.67%	-2.25%	-28.45%	746.88%
Net Cash Per Share	8.64	20.02	29.40	59.11	75.25	199.64
Filing Date Shares Outstanding	6.58	6.58	1.46	0.84	0.59	0.54
Total Common Shares Outstanding	6.58	6.39	1.45	0.84	0.59	0.51
Working Capital	38.13	52.27	34.66	38.33	40.76	57.64
Book Value Per Share	5.84	8.21	24.30	46.21	70.40	114.92
Tangible Book Value	38.43	52.48	35.31	38.82	41.55	58.98
Tangible Book Value Per Share	5.84	8.21	24.30	46.21	70.40	114.92
Machinery	0.19	0.13	0.12	-	-	-

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q